Abstract
The present review considers the potential pleiotropic effects of statins and the evidence indicative of the “real world” benefit from these effects in patients with cardiovascular disease (CVD). Some of these cholesterol-independent effects of statins involve improved endothelial function, stability of atherosclerotic plaques, attenuation of oxidative stress and inflammation, as well as inhibition of the thrombogenic response. Clinical evidence from early statin administration in acute coronary syndromes and in revascularisation procedures is reported. Moreover, the “metabolic” effects of statin treatment, such as renal function improvement and reduction in serum uric acid levels, in patients with stable coronary heart disease are discussed. Evidence suggests that in high CVD risk patient groups pleiotropic effects of statins may play a role in the reduction of morbidity and mortality. However, this concept requires proof in appropriately designed trials that will include clinically relevant end points in order to set specific targets in new CVD-related biomarkers, in addition to lipid levels, that should be used to fully assess the statin contribution to CVD treatment.
Keywords: Dyslipidemia, statins, pleiotropic effects, clinical evidence, cardiovascular disease, endothelium, inflammation, acute coronary syndrome
Current Pharmaceutical Design
Title: Pleiotropic Effects of Statins - Clinical Evidence
Volume: 15 Issue: 5
Author(s): Vasilios G. Athyros, Anna I. Kakafika, Konstantinos Tziomalos, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Dyslipidemia, statins, pleiotropic effects, clinical evidence, cardiovascular disease, endothelium, inflammation, acute coronary syndrome
Abstract: The present review considers the potential pleiotropic effects of statins and the evidence indicative of the “real world” benefit from these effects in patients with cardiovascular disease (CVD). Some of these cholesterol-independent effects of statins involve improved endothelial function, stability of atherosclerotic plaques, attenuation of oxidative stress and inflammation, as well as inhibition of the thrombogenic response. Clinical evidence from early statin administration in acute coronary syndromes and in revascularisation procedures is reported. Moreover, the “metabolic” effects of statin treatment, such as renal function improvement and reduction in serum uric acid levels, in patients with stable coronary heart disease are discussed. Evidence suggests that in high CVD risk patient groups pleiotropic effects of statins may play a role in the reduction of morbidity and mortality. However, this concept requires proof in appropriately designed trials that will include clinically relevant end points in order to set specific targets in new CVD-related biomarkers, in addition to lipid levels, that should be used to fully assess the statin contribution to CVD treatment.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Kakafika I. Anna, Tziomalos Konstantinos, Karagiannis Asterios and Mikhailidis P. Dimitri, Pleiotropic Effects of Statins - Clinical Evidence, Current Pharmaceutical Design 2009; 15 (5) . https://dx.doi.org/10.2174/138161209787315729
DOI https://dx.doi.org/10.2174/138161209787315729 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Binding Interactions of Forskolin with Human Serum Albumin: Insights from In silico and Spectroscopic Studies
Current Chemical Biology Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Current Vascular Pharmacology Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - First Part: Therapy
Current Hypertension Reviews Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Endothelin-1 and Human Platelets
Current Vascular Pharmacology Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design